Navigation Links
Eribulin mesylate demonstrated anti-tumor activity in patients with advanced breast cancer
Date:5/30/2008

Woodcliff Lake, N.J., May 15, 2008The investigational chemotherapeutic agent eribulin mesylate (E7389) demonstrated activity in a heavily pretreated population of women with locally advanced or metastatic breast cancer, according to results of a multi-center Phase II clinical trial. The study also suggests that eribulin mesylate has a manageable tolerability profile, with a low incidence of Grade 3 (severe) and no Grade 4 (disabling or life-threatening) neuropathy. These data (abstract #1084) will be presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) on Monday, June 2 from 2 to 6 p.m. at S Hall A1 of McCormick Place.

The anti-tumor activity of eribulin mesylate, as observed in this study, is encouraging, given the limited treatment options for women with advanced breast cancer who have previously received multiple lines of therapy, said lead investigator Linda T. Vahdat, MD, of Weill Cornell Medical College in New York. The subjects in this trial had received a median of four prior chemotherapy regimens that included an anthracycline, a taxane and capecitabine.

About Study 211 Study 211 is a Phase II, open-label, single-arm study evaluating the efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer who had received an anthracycline, a taxane and capecitabine as prior therapy, and who were refractory to their last chemotherapy regimen, as documented by progression on or within six months of that therapy.

Of 299 patients enrolled in the study, 291 were treated with eribulin mesylate. The median age of those patients was 56 years (range: 26-80 years). Eribulin mesylate was administered at a dose of 1.4mg/m2 as a 2- to 5-minute intravenous infusion on Days 1 and 8 of a 21-day cycle. Patients received a median of four cycles of eribulin mesylate (range 1-27). No premedication to prevent hypersensitivity was required.

Two-hundred sixty-n
'/>"/>

Contact: Judee Shuler
201-746-2241
Eisai Inc.
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. UM coral scientist Peter Glynn wins award for scholarly activity
2. Blood pressure drug telmisartan shows powerful activity against stroke
3. Cold Spring Harbor Protocols highlights a method that captures cell growth and activity
4. CAPHOSOL relieves oral mucositis and improves quality-of-life in cancer patients
5. Cell-based therapy shows promise in patients with Parkinsons disease
6. Scientists test device to track medication adherence in patients with HIV/AIDS
7. Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology
8. New chemotherapy combo produces side effects, but no extra efficacy, in early breast cancer patients
9. Pregnant patients lose out in breast cancer treatment; a new approach is needed
10. Mental stress reduces blood flow to the heart in patients with gene variation
11. 2 new therapies show promise for cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/20/2015)... 2015 Research and Markets ( ... "India Sensors Market Forecast and Opportunities 2020" ... sensor market is projected to grow at a ... electronics, automotive, industrial and healthcare sectors are the ... In addition, adoption of MEMS technology in sensors ...
(Date:3/19/2015)... OXFORD, Conn. , March 19, 2015  NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce market, ... featured in a news clip that aired this week on ... http://www.myfoxdc.com/ ) . In a segment "The Next ... smart wallet ,a new way to pay, and ,a really ...
(Date:3/17/2015)... 2015  MecklerMedia Corporation (OTCQX: MECK) announced its ... robots ever held in New York ... 11-13, 2015 at the Javits Convention Center. ... include: Acorn Product Development; Axis NJ; c-Link Systems; ... Littler; NewBotic Corporation; Neya Systems LLC; Reliabotics; RoboKind; ...
Breaking Biology News(10 mins):India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
... are an important food source for fish and other aquatic ... this week in the Proceedings of the National Academy ... diets are supported by material that originates on land in ... to clarifying the role that watershed inputs play in aquatic ...
... BUFFALO, N.Y. -- An innovative, educational computing platform developed ... the cloud (remote, high-capacity, scalable servers) is helping UB ... new level. Soon, high-school and middle-school students will benefit ... by UB faculty members with a $250,000 National Science ...
... and Nanyang Technological University (NTU) are collaborating to enhance ... with oil., If successful, the wider application of the ... companies here to produce distilled water for their industrial ... at Singapore,s Jurong Island, which produce a lot of ...
Cached Biology News:Aquatic food web tied to land 2With cloud computing, the mathematics of evolution may get easier to learn 2With cloud computing, the mathematics of evolution may get easier to learn 3With cloud computing, the mathematics of evolution may get easier to learn 4memsys-NTU partnership to enhance water desalination technology 2
(Date:3/27/2015)... , March 27, 2015  Neogen Corporation (NASDAQ: ... adopted a prearranged trading plan in accordance with Securities ... Chairman and CEO of Neogen Corporation, is a minority ... Corporation common stock. Herbert does not have ... appropriate. The filing is only for a portion of ...
(Date:3/27/2015)... , March 27, 2015  Peter Walter was ... Science for his pioneering work on how proteins are ... of a regulatory mechanism that cells use to handle ... Walter is a professor of biochemistry at the University ... for treating a range of human diseases related to ...
(Date:3/27/2015)... 27, 2015 WuXi PharmaTech (Cayman) Inc. ... capability and technology platform company serving the global ... that an Investigational New Drug (IND) application for ... arthritis has been accepted for review by the ... In September 2012, MedImmune, the global biologics ...
(Date:3/27/2015)... Governor Andrew M. Cuomo today announced ... - the world’s largest business idea competition with $5 ... $1 million, six $500,000 awards and four $250,000 awards. ... compete for prizes that will turn ideas with high ... York region. , "Last year's successful 43North competition ...
Breaking Biology Technology:Neogen CEO adopts 10b5-1 Trading Plan 2German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 2German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 3Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 2Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 3Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 4Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 5
... CLAREMONT, Calif., May 13 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech ... finalization of an agreement establishing a joint ... product., On May 9, General Manager ... Mr. Ruijun Li and his associates visited ...
... - Regulated Information, ThromboGenics NV (Euronext Brussels: ... vascular disease, eye disease and,cancer, is today issuing ... ended,31 March 2008., Prof. Desire Collen, CEO ... "ThromboGenics, clinical development programs,are continuing to make the ...
... Conn., May 13 Biodel Inc. (Nasdaq:,BIOD) today announced ... NASDAQ Biotechnology Index (NBI), effective as of the market,s ... to be included in the NASDAQ Biotechnology Index and,believe ... of its goals," stated Dr. Solomon Steiner, Chairman and ...
Cached Biology Technology:Kiwa Bio-Tech Confirms Joint Venture Agreement With Shijiazhuang Huaxing Animal Medicine Co., Ltd. 2Kiwa Bio-Tech Confirms Joint Venture Agreement With Shijiazhuang Huaxing Animal Medicine Co., Ltd. 3ThromboGenics N.V. - Business Update 2ThromboGenics N.V. - Business Update 3ThromboGenics N.V. - Business Update 4ThromboGenics N.V. - Business Update 5ThromboGenics N.V. - Business Update 6ThromboGenics N.V. - Business Update 7Biodel Inc. Added to NASDAQ Biotechnology Index 2
... Purified Tyrosine Hydroxylase (Ser40) Polyclonal ... raised against synthetic phosphopeptide corresponding ... the phospho-Ser40 of rat Tyrosine ... purified by sequential chromatography on ...
...
Mouse H60 Allophycocyanin MAb (Clone 205326) ENTREZ GeneID: 15101...
Can be used for the quantitative recovery of small amounts of nucleic acids within dilute solutions. 5mg/ml...
Biology Products: